Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for AD and dementia with Lewy bodies (DLB) (1, 5, 6), whereas APOE2, a well-established longevity determinant, affords protection against the disease (7, 8).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [1]
In the citing paper
“Familial Alzheimer’s disease, which has an autosomal dominant form of inheritance and early onset, has been associated with mutations in APP, PSEN1 and PSEN2, three genes that are critical for beta amyloid (Aβ) production61.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [61]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Despite the lack of MAPT mutations in AD, it is likely that tau dysfunction still contributes to AD ris”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“, none of these candidates has been proved to consistently influence disease risk or onset age in more than a handful of sample”
BackgroundSelf-citationTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 1×
“Although the total number of AD risk genes and their precise identity remain elusive, there is good evidence suggesting that in combination they have a substantial impact on disease predisposition and age of onse”
BackgroundBrookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787 · cited 1×
“It has been estimated that delaying the onset of AD by just a few years could substantially reduce the number of patients with AD over the next 50 year”
BackgroundIron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355
Whole-Genome Patterns of Common DNA Variation in Three Human Populations
Hinds, D. A., Stuve, L. L., Nilsen, G. B., Halperin, E., Eskin, E., Ballinger, D. G., Frazer, K. A., & Cox, D. R. (2005) · Science · doi:10.1126/science.1105436 · Cited by 1,170
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167
Homozygous prion protein genotype predisposes to sporadic Creutzfeldt–Jakob disease
Palmer, M. S., Dryden, A. J., Hughes, J. T., & Collinge, J. (1991) · Nature · doi:10.1038/352340a0 · Cited by 890 · cited 1×
“This was attributed to a decreased tendency of heterozygous PRP to form amyloi”
BackgroundA common inversion under selection in Europeans
Stefansson, H., Helgason, A., Thorleifsson, G., Steinthorsdottir, V., Masson, G., Barnard, J., Baker, A., Jonasdottir, A., Ingason, A., Gudnadottir, V. G., et al. (2005) · Nature Genetics · doi:10.1038/ng1508 · Cited by 828 · cited 1×
“The extensive LD is explained by an inversion of a ∼900 kb interval that gives rise to two heterologous haplotype clades — denoted H1 and H2 — between which recombination is prevente”
BackgroundAlzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677 · cited 1×
“Aβ production and clearance have been shown to be regulated by cholesterol, and drugs that inhibit cholesterol synthesis lower Aβ in cellular and animal model”
BackgroundSelf-citationAndersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655
Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569 · cited 1×
“Three groups have reported the results of AD GWA analyse”
ResultSporadic and familial CJD: classification and characterisation
Gambetti, P., Kong, Q., Zou, W., Parchi, P., & Chen, S. G. (2003) · British Medical Bulletin · doi:10.1093/bmb/66.1.213 · Cited by 569 · cited 1×
“More than two dozen different amino-acid-changing mutations in PRNP that are transmitted in an autosomal-dominant fashion with nearly 100% penetrance have been identified as causes of familial prion disease”
BackgroundEstrogen reduces neuronal generation of Alzheimer β-amyloid peptides
Xu, H., Gouras, G. K., Greenfield, J. P., Vincent, B., Naslund, J., Mazzarelli, L., Fried, G., Jovanovic, J. N., Seeger, M., Relkin, N. R., et al. (1998) · Nature Medicine · doi:10.1038/nm0498-447 · Cited by 560
Assessment of cumulative evidence on genetic associations: interim guidelines
Ioannidis, J. P., Boffetta, P., Little, J., O'Brien, T. R., Uitterlinden, A. G., Vineis, P., Balding, D. J., Chokkalingam, A., Dolan, S. M., Flanders, W. D., et al. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dym159 · Cited by 552
Human laminopathies: nuclei gone genetically awry
Capell, B. C., & Collins, F. S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1906 · Cited by 527
High-Resolution Whole-Genome Association Study of Parkinson Disease
Maraganore, D. M., de Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca, W. A., Pant, P. V. K., Frazer, K. A., Cox, D. R., & Ballinger, D. G. (2005) · The American Journal of Human Genetics · doi:10.1086/496902 · Cited by 508 · cited 1×
“Interestingly, however, the gene maps within ∼15 kb of semaphorin 4A ( SEMA4A ), a homologue of SEMA5A , which has been associated with risk for Parkinson's disease (PD) in a recent GWA stud”
BackgroundCandidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499 · cited 1×
“Three groups have reported the results of AD GWA analyse”
ResultGAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers
Reiman, E. M., Webster, J. A., Myers, A. J., Hardy, J., Dunckley, T., Zismann, V. L., Joshipura, K. D., Pearson, J. V., Hu-Lince, D., Huentelman, M. J., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.022 · Cited by 487
Sloane, P. D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., & Sudha, S. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140525 · Cited by 461 · cited 1×
“It has been estimated that delaying the onset of AD by just a few years could substantially reduce the number of patients with AD over the next 50 year”
BackgroundThe nicotinic receptor β2 subunit is mutant in nocturnal frontal lobe epilepsy
Fusco, M. D., Becchetti, A., Patrignani, A., Annesi, G., Gambardella, A., Quattrone, A., Ballabio, A., Wanke, E., & Casari, G. (2000) · Nature Genetics · doi:10.1038/81566 · Cited by 448
Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology
HUANG, X., MOIR, R. D., TANZI, R. E., BUSH, A. I., & ROGERS, J. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.012 · Cited by 425 · cited 1×
“In addition, the binding of metals to Aβ has been shown to modulate several physiochemical properties of the peptide, along with its aggregation rate and pathogenicity, and iron has also been demonstrated to regulate the translation of AP”
BackgroundSelf-citationHill, O. W. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.507.175 · Cited by 400
Hu, J., Igarashi, A., Kamata, M., & Nakagawa, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104068200 · Cited by 360
Sayed-Tabatabaei, F. A., Oostra, B. A., Isaacs, A., van Duijn, C. M., & Witteman, J. C. M. (2006) · Circulation Research · doi:10.1161/01.res.0000223145.74217.e7 · Cited by 353
Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions
Loeffler, D. A., Connor, J. R., Juneau, P. L., Snyder, B. S., Kanaley, L., DeMaggio, A. J., Nguyen, H., Brickman, C. M., & LeWitt, P. A. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020710.x · Cited by 334 · cited 1×
“Iron has been found to be increased in the brains of patients with A”
BackgroundMuscle and neuronal nicotinic acetylcholine receptors: Structure, function and pathogenicity
Kalamida, D., Poulas, K., Avramopoulou, V., Fostieri, E., Lagoumintzis, G., Lazaridis, K., Sideri, A., Zouridakis, M., & Tzartos, S. J. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05935.x · Cited by 333 · cited 1×
“They are widely expressed in the CNS, where the β2 subunit is particularly abundant and forms heteropentameric α4β2 receptors with α4 subunit”
BackgroundHemming, M. L., & Selkoe, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 332
Loss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316
Yamamoto, A., Shin, R., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., & Kitamoto, T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.t01-1-01061.x · Cited by 313 · cited 1×
“More recently it was suggested that iron might also have a role in aggregating hyperphosphorylated tau into insoluble paired helical filaments, one of the core components of NFT”
BackgroundThe Number of Trait Loci in Late-Onset Alzheimer Disease
Daw, E. W., Payami, H., Nemens, E. J., Nochlin, D., Bird, T. D., Schellenberg, G. D., & Wijsman, E. M. (2000) · The American Journal of Human Genetics · doi:10.1086/302710 · Cited by 295 · cited 1×
“Although the total number of AD risk genes and their precise identity remain elusive, there is good evidence suggesting that in combination they have a substantial impact on disease predisposition and age of onse”
BackgroundGrupe, A., Abraham, R., Li, Y., Rowland, C., Hollingworth, P., Morgan, A., Jehu, L., Segurado, R., Stone, D., Schadt, E., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm031 · Cited by 289 · cited 1×
“Three groups have reported the results of AD GWA analyse”
ResultVariation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
Kehoe, P. G., Russ, C., McIlroy, S., Williams, H., Holmans, P., Holmes, C., Liolitsa, D., Vahidassr, D., Powell, J., McGleenon, B., et al. (1999) · Nature Genetics · doi:10.1038/5009 · Cited by 260
Myers, A. J., Pittman, A. M., Zhao, A. S., Rohrer, K., Kaleem, M., Marlowe, L., Lees, A., Leung, D., McKeith, I. G., Perry, R. H., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.018 · Cited by 255
Yamamoto, A., Shin, R., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., & Kitamoto, T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01061.x · Cited by 246
Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression
Ohrui, T., Tomita, N., Sato-Nakagawa, T., Matsui, T., Maruyama, M., Niwa, K., Arai, H., & Sasaki, H. (2004) · Neurology · doi:10.1212/01.wnl.0000140705.23869.e9 · Cited by 246
Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease.
Brewer, G. J. (2007) · PubMed · Cited by 245
Offe, K., Dodson, S. E., Shoemaker, J. T., Fritz, J. J., Gearing, M., Levey, A. I., & Lah, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4946-05.2006 · Cited by 245
Family-Based Association between Alzheimer's Disease and Variants in UBQLN1
Bertram, L., Hiltunen, M., Parkinson, M., Ingelsson, M., Lange, C., Ramasamy, K., Mullin, K., Menon, R., Sampson, A. J., Hsiao, M. Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042765 · Cited by 229 · cited 1×
“It also maps within ∼60 kb of ubiquilin 4 ( UBQLN4 ), a homologue of UBQLN1 , which has been associated with risk for AD in family sample”
BackgroundSelf-citationReynolds, C. H., Garwood, C. J., Wray, S., Price, C., Kellie, S., Perera, T., Zvelebil, M., Yang, A., Sheppard, P. W., Varndell, I. M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709715200 · Cited by 226 · cited 1×
“Moreover, growth factor receptor-bound protein 2, which binds GAB2, has been reported to bind ta”
BackgroundSavaskan, E., Hock, C., Olivieri, G., Bruttel, S., Rosenberg, C., Hulette, C., & Müller-Spahn, F. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00259-1 · Cited by 217
Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211 · cited 1×
“, and that nicotine, possibly by activating nAChRs, can mediate the toxic effects of Aβ and might also be involved in phosphorylating tau in vitro and in vivo”
BackgroundGenome‐wide significance for dense SNP and resequencing data
Hoggart, C. J., Clark, T. G., De Iorio, M., Whittaker, J. C., & Balding, D. J. (2008) · Genetic Epidemiology · doi:10.1002/gepi.20292 · Cited by 209
Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors
Zoli, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1235 · Cited by 208 · cited 1×
“Furthermore, aged CHRNB2 -knockout mice display significant impairments in visual–spatial memory tasks, suggesting that β2-containing nAChRs contribute to both neuronal survival and the maintenance of cognitive performance during agin”
BackgroundThe Role of Heredity in Late-Onset Alzheimer Disease and Vascular Dementia: A Twin Study
Bergem, A. L. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830150090013 · Cited by 206
Yamazaki, H., Bujo, H., Kusunoki, J., Seimiya, K., Kanaki, T., Morisaki, N., Schneider, W. J., & Saito, Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24761 · Cited by 204
Measured Haplotype Analysis of the Angiotensin-I Converting Enzyme Gene
Keavney, B., McKenzie, C. A., Connell, J. M. C., Julier, C., Ratcliffe, P. J., Sobel, E., Lathrop, M., & Farrall, M. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.11.1745 · Cited by 202
The laminopathies: a clinical review
Rankin, J., & Ellard, S. (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00677.x · Cited by 200 · cited 1×
“Alternative splicing of LMNA produces two isoforms (lamin A and lamin C), which are ubiquitously expressed, and mutations in LMNA have been found to cause a large number of different disorder”
BackgroundLiu, Y., & Rohrschneider, L. R. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02425-0 · Cited by 199 · cited 1×
“GAB2 is a member of a family of evolutionarily highly conserved scaffolding/ adaptor proteins that are involved in multiple signalling pathways and, in particular, in the transduction of cytokines and in growth-receptor signallin”
BackgroundEckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
Andersen, O. M., Schmidt, V., Spoelgen, R., Gliemann, J., Behlke, J., Galatis, D., McKinstry, W. J., Parker, M. W., Masters, C. L., Hyman, B. T., et al. (2006) · Biochemistry · doi:10.1021/bi052120v · Cited by 178
Miners, J. S., Ashby, E., Van Helmond, Z., Chalmers, K. A., Palmer, L. E., Love, S., & Kehoe, P. G. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00885.x · Cited by 166 · cited 1×
“More recently, ACE1 activity has been reported to be increased in AD brains in proportion to the parenchymal Aβ loa”
BackgroundRademakers, R., Melquist, S., Cruts, M., Theuns, J., Del-Favero, J., Poorkaj, P., Baker, M., Sleegers, K., Crook, R., De Pooter, T., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi361 · Cited by 164
Tau haplotypes regulate transcription and are associated with Parkinson's disease
Kwok, J. B. J., Teber, E. T., Loy, C., Hallupp, M., Nicholson, G., Mellick, G. D., Buchanan, D. D., Silburn, P. A., & Schofield, P. R. (2004) · Annals of Neurology · doi:10.1002/ana.10826 · Cited by 159 · cited 1×
“The observation that neither this nor any other SNP that is in LD with the H1c/H1B subclade currently shows an association that is as pronounced as the H2 versus H1 comparison for both PD and PSP does not preclude the interpretation that the real pathogenetically active MAPT variant might actually be found on the H2 b…”
BackgroundBinding of cystatin C to Alzheimer’s amyloid β inhibits in vitro amyloid fibril formation
Sastre, M., Calero, M., Pawlik, M., Mathews, P. M., Kumar, A. R., Danilov, V., Schmidt, S. D., Nixon, R. A., Frangione, B., & Levy, E. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.006 · Cited by 151
Cystatin C modulates cerebral β-amyloidosis
Kaeser, S. A., Herzig, M. C., Coomaraswamy, J., Kilger, E., Selenica, M.-L., Winkler, D. T., Staufenbiel, M., Levy, E., Grubb, A., & Jucker, M. (2007) · Nature Genetics · doi:10.1038/ng.2007.23 · Cited by 150
Genetic Association of a Cystatin C Gene Polymorphism With Late-Onset Alzheimer Disease
Finckh, U., von der Kammer, H., Velden, J., Michel, T., Andresen, B., Deng, A., Zhang, J., Müller-Thomsen, T., Zuchowski, K., Menzer, G., et al. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1579 · Cited by 149
The role of nicotinic acetylcholine receptors in Alzheimer’s disease
Oddo, S., & LaFerla, F. M. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2005.12.080 · Cited by 142
Alzheimer's disease in Finnish twins
Räihä, I. J., Rajala, T., Sourander, L., Kaprio, J. A., & Koskenvuo, M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91272-6 · Cited by 139
Lahiri, D., Maloney, B., Riyaz Basha, M., Wen Ge, Y., & Zawia, N. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362164 · Cited by 134
Hemming, M. L., Selkoe, D. J., & Farris, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.004 · Cited by 128
Wu, J., Kuo, Y., George, A. A., Xu, L., Hu, J., & Lukas, R. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400335200 · Cited by 123 · cited 1×
“It has been suggested that Aβ might directly inhibit the α4β2 comple”
BackgroundRobson, K. J. H., Lehmann, D. J., Wimhurst, V. L. C., Livesey, K. J., Combrinck, M., Merryweather-Clarke, A. T., Warden, D. R., & Smith, A. D. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015552 · Cited by 120 · cited 1×
“It is interesting to note that a recent AD association study concluded that the TF Ser allele might act epistatically with the Tyr allele at another locus that is involved in iron metabolism (rs1800562 (Cys282Tyr) in the haemochromatosis ( HFE ) gene on chromosome 6p22 (Ref”
BackgroundVinters, H. V., Nishimura, G. S., Secor, D. L., & Pardridge, W. M. (1990) · Europe PMC (PubMed Central) · Cited by 118
The role of the nicotinic acetylcholine receptors in sleep-related epilepsy
Marini, C., & Guerrini, R. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.030 · Cited by 113
The Role of Cystatin C in Cerebral Amyloid Angiopathy and Stroke: Cell Biology and Animal Models
Levy, E., Jaskólski, M., & GRUBB, A. O. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00562.x · Cited by 110 · cited 1×
“It is important to add that CAA lesions are also observed in AD brains, where they are composed of Aβ bound to Cys”
BackgroundUntangling the tau gene association with neurodegenerative disorders
Pittman, A. M., Fung, H.-C., & de Silva, R. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl190 · Cited by 110 · cited 1×
“org/">PDGene database) and in at least two related disorders (progressive supranuclear palsy (PSP) and corticobasal degeneratio”
BackgroundA polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease
Crawford, F. C., Freeman, M. J., Schinka, J. A., Abdullah, L. I., Gold, M., Hartman, R., Krivian, K., Morris, M. D., Richards, D., Duara, R., et al. (2000) · Neurology · doi:10.1212/wnl.55.6.763 · Cited by 109
LR11, a Mosaic LDL Receptor Family Member, Mediates the Uptake of ApoE-Rich Lipoproteins In Vitro
Taira, K., Bujo, H., Hirayama, S., Yamazaki, H., Kanaki, T., Takahashi, K., Ishii, I., Miida, T., Schneider, W. J., & Saitō, Y. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0901.094500 · Cited by 109
PRNP Val129 homozygosity increases risk for early‐onset Alzheimer's disease
Dermaut, B., Croes, E. A., Rademakers, R., Van Den Broeck, M., Cruts, M., Hofman, A., Van Duijn, C. M., & Van Broeckhoven, C. (2003) · Annals of Neurology · doi:10.1002/ana.10507 · Cited by 102
Prion protein (PrPc) promotes β-amyloid plaque formation
Schwarze-Eicker, K., Keyvani, K., Goertz, N., Westaway, D. A., Sachser, N., & Paulus, W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.10.004 · Cited by 100
Sármay, G., Angyal, A., Kertész, Á., Maus, M., & Medgyesi, D. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.017 · Cited by 97
Neuronal LR11/sorLA expression is reduced in mild cognitive impairment
Sager, K. L., Wuu, J., Leurgans, S. E., Rees, H. D., Gearing, M., Mufson, E. J., Levey, A. I., & Lah, J. J. (2007) · Annals of Neurology · doi:10.1002/ana.21190 · Cited by 96
The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments
Mackenzie, I. R., & Rademakers, R. (2007) · Neurogenetics · doi:10.1007/s10048-007-0102-4 · Cited by 95 · cited 1×
“However, MAPT mutations were found to cause another form of dementia, frontotemporal lobar degeneration with parkinsonism linked to chromosome 17 (FTDP-17”
BackgroundNizzari, M., Venezia, V., Repetto, E., Caorsi, V., Magrassi, R., Gagliani, M. C., Carlo, P., Florio, T., Schettini, G., Tacchetti, C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610146200 · Cited by 93
Palm, D. E., Knuckey, N. W., Primiano, M. J., Spangenberger, A. G., & Johanson, C. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00520-z · Cited by 92 · cited 1×
“It is ubiquitously expressed, is found in high levels in most body fluids — in particular the CSF — and is upregulated following acute injur”
BackgroundKauwe, J. S. K., Cruchaga, C., Mayo, K., Fenoglio, C., Bertelsen, S., Nowotny, P., Galimberti, D., Scarpini, E., Morris, J. C., Fagan, A. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801227105 · Cited by 89
Expression of cystatin C in rat, monkey and human brains
Yasuhara, O., Hanai, K., Ohkubo, I., Sasaki, M., McGeer, P. L., & Kimura, H. (1993) · Brain Research · doi:10.1016/0006-8993(93)90941-f · Cited by 74 · cited 1×
“In the brain it is produced mostly by astrocytes and activated microglia, but also by neuron”
BackgroundA polymorphism in the tau gene associated with risk for Alzheimer's disease
Bullido, M. J., Aldudo, J., Frank, A., Coria, F., Ávila, J., & Valdivieso, F. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00893-9 · Cited by 68
Increased frequency of the transferrin C2 subtype in Alzheimerʼs disease
van Rensburg, S. J., Carstens, M. E., Potocnik, F. C. V., Aucamp, A. K., & Taljaard, J. J. F. (1993) · NeuroReport · doi:10.1097/00001756-199309000-00015 · Cited by 68
Faraone, S. V., Biederman, J., Mennin, D., & Russell, R. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980207)81:1<108::aid-ajmg18>3.0.co;2-n · Cited by 67
Tau gene polymorphisms and apolipoprotein E ε4 may interact to increase risk for Alzheimer’s disease
Lilius, L., Fabre, S. F., Basun, H., Forsell, C., Axelman, K., Mattila, K. J., Andreadis, A., Viitanen, M. H., Winblad, B. G., Fratiglioni, L., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00833-2 · Cited by 62
Nagai, A., Ryu, J. K., Terashima, M., Tanigawa, Y., Wakabayashi, K., McLarnon, J. G., Kobayashi, S., Masuda, J., & Kim, S. U. (2005) · Brain Research · doi:10.1016/j.brainres.2005.10.063 · Cited by 59 · cited 1×
“However, injection of CysC into the rat hippocampus was shown to induce apoptotic cell death, suggesting that hyperactivity of this protease inhibitor might be neurotoxi”
BackgroundAlzheimer disease-associated cystatin C variant undergoes impaired secretion
Benussi, L., Ghidoni, R., Steinhoff, T., Alberici, A., Villa, A., Mazzoli, F., Nicosia, F., Barbiero, L., Broglio, L., Feudatari, E., et al. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00012-3 · Cited by 59
The presence of valine at residue 129 in human prion protein accelerates amyloid formation
Baskakov, I. V., Disterer, P., Breydo, L., Shaw, M. K., Gill, A. C., James, W., & Tahiri‐Alaoui, A. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.03.075 · Cited by 57 · cited 1×
“, although a similar finding was earlier reported for the Val allel”
ResultTohgi, H., Utsugisawa, K., Yoshimura, M., Nagane, Y., & Mihara, M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00205-5 · Cited by 56 · cited 1×
“, and several studies have suggested that an age-dependent decrease in protein and/or mRNA levels of α4 and, in particular, β2 subunits occurs in the cortex and hippocampus of healthy individual”
BackgroundHenschke, P. J., Bell, D. A., & Cape, R. D. T. (1978) · Tissue Antigens · doi:10.1111/j.1399-0039.1978.tb01308.x · Cited by 56 · cited 1×
“Currently AlzGene includes nearly 1,100 individual studies (the first of which was published 30 years ag”
BackgroundPedersen, N. L., Posner, S. F., & Gatz, M. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1608 · Cited by 55
Cook, L. J., Ho, L. W., Taylor, A., Brayne, C., Evans, J. G., Xuereb, J. H., Cairns, N. J., Pritchard, A. L., Lemmon, H. A., Mann, D. M. A., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.01.016 · Cited by 53
Takeda, S. (2008) · Frontiers in Bioscience · doi:10.2741/2839 · Cited by 51 · cited 1×
“Another involvement of ACE1 in AD pathogenesis could be due to its role in blood pressure regulation, as some studies have shown an increased risk for AD in indviduals with high mid-life blood pressur”
BackgroundPapassotiropoulos, A., Lambert, J.-C., Wavrant-De Vrièze, F., Wollmer, M. A., von der Kammer, H., Streffer, J. R., Maddalena, A., Huynh, K.-D., Wolleb, S., Lütjohann, D., et al. (2005) · Neurodegenerative Diseases · doi:10.1159/000090362 · Cited by 51
Unexpected Intracellular Localization of the AMD‐Associated Cystatin C Variant
Paraoan, L., Ratnayaka, A., Spiller, D. G., Hiscott, P., White, M. R. H., & Grierson, I. (2004) · Traffic · doi:10.1111/j.1600-0854.2004.00230.x · Cited by 47
Kawamata, J., & Shimohama, S. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4201 · Cited by 43
Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation
Lewis, P. A., Tattum, M. H., Jones, S., Bhelt, D., Batchelor, M., Clarke, A. R., Collinge, J., & Jackson, G. S. (2006) · Journal of General Virology · doi:10.1099/vir.0.81630-0 · Cited by 43 · cited 1×
“This agrees with recent observations of PRP-amyloid formatio”
ResultZerbinatti, C., Cordy, J. M., Chen, C.-D., Guillily, M. D., Suon, S., Ray, W. J., Seabrook, G. R., Abraham, C. R., & Wolozin, B. L. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-5 · Cited by 40 · cited 1×
“More recently it was shown that 25-hydroxycholesterol, which is produced by C25H, can lead to changes in Aβ levels by altering the processing and trafficking of APP in vitro”
BackgroundThe Effect of Transferrin Polymorphisms on Iron Metabolism
Lee, P. L., Ho, N. J., Olson, R., & Beutler, E. (1999) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.1999.0267 · Cited by 35 · cited 1×
“This hypothesis was not confirmed in at least two studie”
BackgroundAssociation study of the GAB2 gene with the risk of developing Alzheimer's disease
Chapuis, J., Hannequin, D., Pasquier, F., Bentham, P., Brice, A., Leber, I., Frebourg, T., Deleuze, J.-F., Cousin, E., Thaker, U., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.006 · Cited by 35 · cited 1×
“Although the association between GAB2 and AD risk was not found to be significant in a more recent study that investigated case–control samples from France and the U”
BackgroundOf replications and refutations: The status of Alzheimer’s disease genetic research
Bertram, L., & Tanzi, R. E. (2001) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-001-0104-9 · Cited by 34
Self-citationPrion protein gene polymorphism and Alzheimer's disease: one modulatory trait of cognitive decline?
Casadei, V. M., Ferri, C., Calabrese, E., Grimaldi, L. M., Franceschi, M., Veglia, F., Licastro, F., & Mariani, C. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.2.279 · Cited by 31
SstII polymorphic sites in the promoter region of the human cystatin C gene
Balbín, M., & Abrahamson, M. (1991) · Human Genetics · doi:10.1007/bf00201742 · Cited by 23 · cited 1×
“Both of the CST3 SNPs that have been analysed in AlzGene showed significant association with AD, with rs1064039 (Ala25Thr) showing the most pronounced effects in homozygous carriers of the Thr25 allele, and both SNPs are in complete L”
BackgroundThe C2 variant of human serum transferrin retains the iron binding properties of the native protein
Zatta, P. F., Luigi Messori, A., Mauri, P., van Rensburg, S. J., van Zyl, J., Gabrielli, S., & Gabbiani, C. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.04.009 · Cited by 20
Duesing, K., Charpentier, G., Marre, M., Tichet, J., Herçberg, S., Froguel, P., & Gibson, F. (2007) · Diabetologia · doi:10.1007/s00125-007-0857-z · Cited by 15 · cited 1×
“The same allele that was associated with increased risk for AD was also reported to increase risk for type-2 diabetes mellitus in a recent meta-analysi”
BackgroundBiochemical markers of Alzheimer’s disease: wish and reality
Papassotiropoulos, A., & Höck, C. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00348-7 · Cited by 13
Papassotiropoulos, A., Streffer, J. R., Schmid, S., Wollmer, A., Maddalena, A. S., Nitsch, R. M., Hock, C., Tsolaki, M., Iakovidou, Thal, D. R., et al. (2002) · Neurobiology of Aging · Cited by 3
Research works printed but not linked: 1
- Meyer, J. M. & Breitner, J. C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 81, 92–97 (1998). · DOI
Cited by
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
“Mutations in three genes—amyloid precursor protein, presenilin 1, and presenilin 2—cause an early onset, autosomal dominantly inherited AD [17].”
BackgroundSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
“Alzheimer’s disease is a common form of dementia characterized by progressive neurodegeneration and loss of cognitive functions of the brain, and much of the genetic variation implicated in Alzheimer’s disease is associated with amyloid precursor protein, transmembrane proteins, and apolipoprotein E4 (Bertram and Tanz…”
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
“Rare mutations in APP and the presenilin components of g-secretase are causes of familial AD, providing one line of evidence for the hypothesis that Ab contributes to the pathogenesis of AD (Bertram and Tanzi, 2008).”
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
“For example, familial Alzheimer’s Disease (AD) patients commonly have mutations in the amyloid precursor protein or presenilin genes which lead to the production and deposition in the brain of increased amounts of the Abeta peptide, characteristic of AD (Bertram and Tanzi, 2008).”
BackgroundThe Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
“Shortly after, mutations in the amyloid precursor protein (APP) gene were identified in familial forms of AD (Bertram and Tanzi, 2008).”
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, Lars
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 768-778
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2018342879
- Cited by
- 747
- References
- 113
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 26 · 2020: 29 · 2019: 34 · 2018: 41 · 2017: 46 · 2016: 37 · 2015: 41 · 2014: 46 · 2013: 59 · 2012: 62
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (5R01-AG23667, R01AG023667)
- National Institute of Mental Health (5R37MH60009, R37MH060009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease genetics, genetic risk factors, candidate genes, meta-analysis, amyloid precursor protein, presenilin 1, presenilin 2, apolipoprotein E, early-onset familial Alzheimer's disease, late-onset Alzheimer's disease, disease pathology, metabolic pathways
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain Chemistry, Humans, Mutation, Risk Factors, Meta-Analysis as Topic, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.